Back to results
US 8,563,512 B2Granted
Neprilysin inhibitors
AssigneeTheravance, Inc.
InventorsCameron Smith, Melissa Fleury, Roland Gendron, Ryan Hudson, Adam D. Hughes
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
Claims22
A compound of formula I:
- where:
- R1 is selected from —OR7 and —NR8R9;
- R2 is H or —P(O)(OH)2 or R2 is taken together with R7 to form —CR18R19— or is taken together with R8 to form —C(O)—;
- X is a —C1-9heteroaryl;
- R3 is absent or is selected from H;
- halo;
- —C0-5alkylene-OH;
- —NH2;
- —C1-6alkyl;
- —CF3;
- —C3-7cycloalkyl;
- —C0-2alkylene-O—C1-6alkyl;
- —C(O)R20;
- —C0-1alkylene-COOR21;
- —C(O)NR22R23;
- —NHC(O)R24;
- ═O;
- —NO2;
- —C(CH3)═N(OH);
- phenyl optionally substituted with one or two groups independently selected from halo, —OH, —CF3, —OCH3, —NHC(O)CH3, and phenyl;
- naphthalenyl;
- pyridinyl;
- pyrazinyl;
- pyrazole optionally substituted with methyl;
- thiophenyl optionally substituted with methyl or halo;
- furanyl;
- and —CH2-morpholinyl;
- and R3, when present, is attached to a carbon atom;
- R4 is absent or is selected from H;
- —OH;
- —C1-6alkyl;
- —C1-2alkylene-COOR35;
- —CH2OC(O)CH(R36)NH2;
- —OCH2OC(O)CH(R36)NH2;
- —OCH2OC(O)CH3;
- —CH2OP(O)(OH)2;
- —CH2CH(OH)CH2OH;
- —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl;
- pyridinyl;
- and phenyl or benzyl optionally substituted with one or more groups selected from halo, —COOR35, —OCH3, —OCF3, and —SCF3;
- and R4, when present, is attached to a carbon or nitrogen atom;
- or R3 and R4 are taken together to form -phenylene-O—(CH2)1-3— or -phenylene-O—CH2—CHOH—CH2—;
- a is 0 or 1;
- R5 is selected from halo, —CH3, —CF3, and —CN;
- b is 0 or an integer from 1 to 3;
- each R6 is independently selected from halo, —OH, —CH3, —OCH3, and —CF3;
- R7 is selected from H, —C1-8alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R10, —C1-6alkylene-NR12R13, —C1-6alkylene-C(O)R31, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
- R10 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR12R13, —CH[CH(CH3)2]—NH2, —CH—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
- and R12 and R13 are independently selected from H, —C1-6alkyl, and benzyl;
- or R12 and R13 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2—O—(CH2)2—;
- and R31 is selected from —O—C1-6alkyl, —O-benzyl, and —NR12R13;
- R32 is —C1-6alkyl or —C0-6alkylene-C6-10aryl;
- R8 is selected from H, —OH, —OC(O)R14, —CH2COOH, —O-benzyl, pyridyl, and —OC(S)NR15R16;
- R14 is selected from H, —C1-6alkyl, —C6-10aryl, —OCH2—C6-10aryl, —CH2O—C6-10aryl, and —NR15R16;
- and R15 and R16 are independently selected from H and —C1-4-alkyl;
- R9 is selected from H, —C1-6alkyl, and —C(O)R17;
- and R17 is selected from H, —C1-6alkyl, —C3-7cycloalkyl, —C6-10aryl, and —C1-9heteroaryl;
- R18 and R19 are independently selected from H, —C1-6alkyl, and —O—C3-7cycloalkyl, or R18 and R19 are taken together to form ═O;
- R20 is selected from H and —C1-6alkyl;
- R21 and R35 are independently selected from H, —C1-6alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R25, —C1-6alkylene-NR27R28, —C1-6alkylene-C(O)R33, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
- R25 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR27R28, —CH—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
- R27 and R28 are independently selected from H, —C1-6alkyl, and benzyl;
- or R27 and R28 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2—O—(CH2)2—;
- R33 is selected from —O—C1-6alkyl, —O-benzyl, and —NR27R28;
- and R34 is —C1-6alkyl or —C0-6alkylene-C6-10aryl;
- R22 and R23 are independently selected from H, —C1-6alkyl, —CH2COOH, —(CH2)2OH, —(CH2)2OCH3, —(CH2)2SO2NH2, —(CH2)2N(CH3)2, —C0-1alkylene-C3-7cycloalkyl, and —(CH2)2-imidazolyl;
- or R22 and R23 are taken together to form a saturated or partially unsaturated —C3-5heterocycle optionally substituted with halo, —OH, —COOH, or —CONH2;
- and optionally containing an oxygen atom in the ring;
- R24 is selected from —C1-6alkyl;
- —C0-1alkylene-O—C1-6alkyl;
- phenyl optionally substituted with halo or —OCH3;
- and —C1-9heteroaryl;
- and
- R36 is selected from H, —CH(CH3)2, phenyl, and benzyl;
- where each alkyl group in R1, R3, and R4 is optionally substituted with 1 to 8 fluoro atoms;
- and;
- where the methylene linker on the biphenyl is optionally substituted with one or two —C1-6alkyl groups or cyclopropyl;
- or a pharmaceutically acceptable salt thereof.
75 more elements
Dependencies are inferred from the claim text.